Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes - Meng, W; Ellsworth, B A; Nirschl, A A (J Med Chem, 2008)
et al.